A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs

Drug Research

Volumn 66, Issue 2, 2015, Pages 74-81

  Kasahara, N ^a   Fukase, H ^b   Ohba, Y ^a   Saito, T ^a   Miyata, K ^a   Iida, S ^a   Takano, Y ^a   Ikeda, S ^a   Harigai, M ^c   Terao, K ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b CPC Clinic   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

anti T2DM drug; drug drug interaction; healthy volunteer; SGLT2 inhibitor; tofogliflozin; urinary glucose excretion

Indexed keywords

ANTIDIABETIC AGENT; GLIMEPIRIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; SITAGLIPTIN; TOFOGLIFLOZIN; VOGLIBOSE; 1 DEOXYNOJIRIMYCIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; BENZHYDRYL DERIVATIVE; CYCLOHEXANE DERIVATIVE; GLUCOSE; GLUCOSIDE; INOSITOL; PHENYLALANINE; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BURN; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG SAFETY; GLUCOSE URINE LEVEL; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; URINARY EXCRETION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG INTERACTION; MIDDLE AGED; URINE; YOUNG ADULT;

1-DEOXYNOJIRIMYCIN; ADULT; BENZHYDRYL COMPOUNDS; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GLUCOSE; GLUCOSIDES; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; MALE; METFORMIN; MIDDLE AGED; PHENYLALANINE; SITAGLIPTIN PHOSPHATE; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; URINE; YOUNG ADULT;

EID: 84957973593     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0035-1549967     Document Type: Article

References (29)

1. World Health Organization Diabetes. Fact sheet N°312. Updated January 2015. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/ Accessed December 18: 2014
2. Rosenbloom A. L., Joe J. R., Young R. S. et al. Emerging epidemic of type 2 diabetes in youth. Diabetes Care: 1999; 22 345 354
3. Stein S. A., Lamos E. M., Davis S. N. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf: 2013; 12 153 175
4. Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol: 2013; 65 317 327
5. Ohtake Y., Sato T., Kobayashi T. et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem: 2012; 55 7828 7840
6. Suzuki M., Honda K., Fukazawa M. et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther: 2012; 341 692 701
7. Kaku K., Watada H., Iwamoto Y. et al., Tofogliflozin 003 Study Group Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol: 2014; 13 65
8. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci: 2011; 32 63 71
9. 13C]tofogliflozin in humans. Clin Pharmacokinet: 2013; 52 463 473
10. Yamane M., Kawashima K., Yamaguchi K. et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes and recombinant human CYP. Xenobiotica: 2015; 45 230 238
11. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Available from http://www.wma.net/en/30publications/10policies/b3/ Accessed December 18: 2014
12. Standl E., Schnell O. Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation. Diab Vasc Dis Res: 2012; 9 163 169
13. U.S. Department of Health and Human Services, Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation 2001. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf Accessed December 18: 2014
14. Maurer T. S., Ghosh A., Haddish-Berhane N. et al. Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. AAPS J: 2011; 13 576 584
15. Yamaguchi K., Kato M., Ozawa K. et al. Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice. J Pharm Sci: 2012; 101 4347 4356
16. Komoroski B., Vachharajani N., Feng Y. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther: 2009; 85 513 519
17. Kapur A., O'Connor-Semmes R., Hussey E. K. et al. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC. BMC Pharmacol Toxicol: 2013; 14 26
18. U.S. Department of Health and Human Services, Food and Drug Administration Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations DRAFT GUIDANCE 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf Accessed December 18: 2014
19. Kimura N., Masuda S., Tanihara Y. et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet: 2005; 20 379 386
20. Chu X. Y., Bleasby K., Yabut J. et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther: 2007; 321 673 683
21. Trovato A., Nuhlicek D. N., Midtling J. E. Drug-nutrient interactions. Am Fam Physician: 1991; 44 1651 1658
22. Nakamura T., Takebe K., Kudoh K. et al. Effect of an alpha-glucosidase inhibitor on intestinal fermentation and faecal lipids in diabetic patients. J Int Med Res: 1993; 21 257 267
23. Tanizawa Y., Kaku K., Araki E. et al. Tofogliflozin 004 and 005 Study Group. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother: 2014; 15 749 766
24. Lajara R. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother: 2014; 15 2565 2585
25. Strojek K., Yoon K. H., Hruba V. et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab: 2011; 13 928 938
26. Hermansen K., Kipnes M., Luo E. et al. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab: 2007; 9 733 745
27. Marre M., Shaw J., Brändle M. et al., LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med: 2009; 26 268 278
28. Kasichayanula S., Liu X., Shyu W. C. et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab: 2011; 13 47 54
29. Macha S., Mattheus M., Pinnetti S. et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: A randomised, open-label, crossover study. J Diab Res Clin Met: 2012; 1 1 14